Results 111 to 120 of about 186,086 (209)
European Journal of Organic Chemistry, Accepted Article.A cyclobutane ring constitutes an interesting scaffold for the development of new materials and drugs. In this work we describe the [2+2] cycloaddition of chalconoid precursors bearing fluorinated and heterocyclic moieties to produce cyclobutane derivatives in solution.
Concepcion Perez-Melero +3 more
wiley +1 more source
Exploration, EarlyView.Using celastrol as a case study, this review summarizes various target discovery strategies for natural products, including chemical proteomics, protein microarray, degradation‐based protein profiling, proteome‐wide label‐free approaches, network pharmacology, target‐based drug screening, and indirect strategies.
Yanbei Tu +5 more
wiley +1 more source
Nanotechnology in brain cancer treatment: The role of gold nanoparticles as therapeutic enhancers
Ibrain, EarlyView.This review highlights the potential of gold nanoparticles (AuNPs) in overcoming the blood‐brain barrier (BBB) to improve brain tumor treatment. By enabling targeted drug delivery and enhancing therapies like radiotherapy, phototherapy, and chemotherapy, AuNPs offer a promising approach for safer, more effective treatments of glioblastoma and other ...
Simona Tarantino +4 more
wiley +1 more source
Mechanisms of enhancer‐driven oncogene activation
International Journal of Cancer, EarlyView.Abstract An aggressive subtype of acute myeloid leukemia (AML) is caused by enhancer hijacking resulting in MECOM overexpression. Several chromosomal rearrangements can lead to this: the most common (inv(3)/t(3;3)) results in a hijacked GATA2 enhancer, and there are several atypical MECOM rearrangements involving enhancers from other hematopoietic ...
Joyce Vriend +2 more
wiley +1 more source
Targeting the Menin–KMT2A interaction in leukemia: Lessons learned and future directions
International Journal of Cancer, EarlyView.Abstract Chromosomal rearrangements involving the Mixed Lineage Leukemia gene (MLL1, KMT2A) are defining a genetically distinct subset in about 10% of human acute leukemias. Translocations involving the KMT2A‐locus at chromosome 11q23 are resulting in the formation of a chimeric oncogene, where the N‐terminal part of KMT2A is fused to a variety of ...
Florian Perner +3 more
wiley +1 more source
Enhancer‐dependent gene regulation in space, time, and malignancies
International Journal of Cancer, EarlyView.Abstract Control of cell‐type‐specific gene activation requires the coordinated activity of distal regulatory elements, including enhancers, whose inputs must be temporally integrated. Dysregulation of this regulatory capacity, such as aberrant usage of enhancers, can result in malignant transformation of cells.
Belinda Blum +2 more
wiley +1 more source
Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia [PDF]
, 2017 et al.,, Uy, Geoffrey L
core +2 more sources
Therapeutic targeting of chromatin alterations in leukemia and solid tumors
International Journal of Cancer, EarlyView.Abstract Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...
Florian Perner +7 more
wiley +1 more source